◎ Sugi Atlas

Atlas / Drug / Ixekizumab

Ixekizumab

drug
On this page

Also known as LY-2439821LY2439821Taltz

Summary

Ixekizumab (CHEMBL1743034) is an approved antibody (ATC L04AC13); indicated across 16 conditions including psoriasis and psoriatic arthritis.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Antibody
  • ATC class: L04AC13
  • Indications: 16 conditions
  • Clinical trials: 57

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL1743034
NameIxekizumab
TypeAntibody
Max phase4
ATCL04AC13

Also known as: Ixekizumab, LY-2439821, LY2439821, Taltz, IXEKIZUMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

16 indications (4 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
psoriasis4MONDO:0005083EFO:0000676
psoriatic arthritis4MONDO:0011849EFO:0003778
immune system disorder4MONDO:0005046EFO:0000540
ankylosing spondylitis3MONDO:0005306EFO:0003898
severe acute respiratory syndrome3MONDO:0005091MONDO:0100096
rheumatoid arthritis2MONDO:0008383EFO:0000685
bullous pemphigoid2MONDO:0019082EFO:0007187
pyoderma2MONDO:0002922HP:0000999
major depressive disorder2MONDO:0002009MONDO:0002009
type 1 diabetes mellitus2MONDO:0005147MONDO:0005147
pityriasis rubra pilaris2MONDO:0100017MONDO:0100017
lichen planus0MONDO:0006572EFO:0009856

4 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 57.

Phase distribution

PhaseTrials
PHASE324
PHASE29
PHASE19
PHASE48
Not specified5
PHASE2/PHASE31
EARLY_PHASE11

Top trials by phase / activity

NCTPhaseStatusTitle
NCT04537689PHASE4RECRUITINGOutcomes With Treatment and Withdraw of Ixekizumab in Patients With Plaque Psoriasis
NCT07352566PHASE4NOT_YET_RECRUITINGUtilization of a Microdevice for Psoriasis and Atopic Dermatitis
NCT03151551PHASE4COMPLETEDA Study of Ixekizumab (LY2439821) Versus Adalimumab in Participants With Psoriatic Arthritis
NCT03573323PHASE4COMPLETEDA Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis
NCT03942042PHASE4COMPLETEDA Study of Ixekizumab (LY2439821) in Participants in Japan With Generalized Pustular Psoriasis and Erythrodermic Psoriasis
NCT04340076PHASE4COMPLETEDDose Reduction of IL17 and IL23 Inhibitors in Psoriasis
NCT05080218PHASE4COMPLETEDCOVID-19 VaccinE Response in Rheumatology Patients
NCT05855967PHASE4COMPLETEDA Study of Ixekizumab (LY2439821) in Participants Aged ≥18 Years With Moderate-to-Severe Plaque or Active Psoriatic Arthritis in India
NCT04527380PHASE3ACTIVE_NOT_RECRUITINGA Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
NCT06374979PHASE2/PHASE3NOT_YET_RECRUITINGEfficacy and Safety of Ixekizumab in Patients with Refractory Guttate Psoriasis
NCT06588283PHASE3ACTIVE_NOT_RECRUITINGIxekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
NCT06945107PHASE3ACTIVE_NOT_RECRUITINGA Study of Switching to Picankibart in Chinese Patients With Plaque Psoriasis With an Inadequate Response to Interleukin-17 Monoclonal Antibody Therapy
NCT01624233PHASE3COMPLETEDA Study in Japanese Participants With Moderate-to-Severe Psoriasis
NCT01646177PHASE3COMPLETEDA Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3)
NCT01695239PHASE3COMPLETEDA Study of Ixekizumab in Participants With Active Psoriatic Arthritis
NCT01777191PHASE3COMPLETEDEvaluation of Ixekizumab Using Auto-Injector or Prefilled Syringe in Participants With Moderate to Severe Plaque Psoriasis
NCT01870284PHASE3WITHDRAWNStudy of Ixekizumab in Participants With Active Ankylosing Spondylitis (AS)
NCT02387801PHASE3COMPLETEDA Study of the Early Activity of Ixekizumab (LY2439821) in Moderate-to-Severe Psoriasis
NCT02513550PHASE3COMPLETEDA Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis
NCT02561806PHASE3COMPLETEDA Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis
NCT02584855PHASE3COMPLETEDA Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
NCT02634801PHASE3COMPLETEDA Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis Naive to Systemic Treatment
NCT02696785PHASE3COMPLETEDA Study of Ixekizumab (LY2439821) in bDMARD-Naive Participants With Radiographic Axial Spondyloarthritis
NCT02696798PHASE3COMPLETEDA Study of Ixekizumab (LY2439821) in TNF Inhibitor Experienced Participants With Radiographic Axial Spondyloarthritis
NCT02718898PHASE3COMPLETEDA Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Genital Psoriasis
NCT02757352PHASE3COMPLETEDA Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
NCT03073200PHASE3COMPLETEDStudy of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis
NCT03129100PHASE3COMPLETEDA Long Term Extension Study of Ixekizumab (LY2439821) in Participants With Axial Spondyloarthritis
NCT03364309PHASE3COMPLETEDA Study of Ixekizumab (LY2439821) in Chinese Participants With Moderate-to-Severe Plaque Psoriasis
NCT04285229PHASE3COMPLETEDA Study of Ixekizumab (LY2439821) in Chinese Participants With Radiographic Axial Spondyloarthritis
NCT04610476PHASE3UNKNOWNImpact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis
NCT04724629PHASE3COMPLETEDSurvival TRial Using CytoKines in COVID-19 (STRUCK Trial)
NCT06588296PHASE3COMPLETEDIxekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight
NCT04589325PHASE2ACTIVE_NOT_RECRUITINGIxekizumab Diabetes Intervention Trial (I-DIT)
NCT07138898PHASE2NOT_YET_RECRUITINGImmunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty
NCT00966875PHASE2COMPLETEDA Study in Patients With Rheumatoid Arthritis
NCT01107457PHASE2COMPLETEDA Study in Participants With Moderate to Severe Psoriasis
NCT03099538PHASE2COMPLETEDIxekizumab in the Treatment of Bullous Pemphigoid
NCT03137160PHASE2COMPLETEDAn Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum
NCT03485976PHASE2COMPLETEDIxekizumab in the Treatment of Pityriasis Rubra Pilaris (PRP)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 15

This page pulls from 15 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclinical_trialsefogtopdb_interactiongtopdb_ligandmeshmondopatent_compoundpharmgkbpharmgkb_guidelinepubchem